D.J. St. Germain’s Alnylam Pharmaceuticals ALNY Stock Holding History

D.J. St. Germain’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.36M	Sell	7,834 -18	-0.2%	-$5.43K	0.08%	130
2026 Q1	$2.6M	Sell	7,852 -5	-0.1%	-$1.7K	0.1%	123
2025 Q4	$3.12M	Sell	7,857 -294	-4%	-$130K	0.12%	112
2025 Q3	$3.72M	Sell	8,151 -843	-9%	-$343K	0.15%	105
2025 Q2	$2.93M	Buy	+8,994	New	+$2.49M	0.13%	110

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.J. St. Germain's ALNY Position: Q2 2026 in Review

D.J. St. Germain reduced its Alnylam Pharmaceuticals (ALNY) stake by 0.23% in Q2 2026, selling an estimated $5.43K and leaving 7,834 shares worth $2.36M. The position accounts for 0.08% of the portfolio, ranked #130.

D.J. St. Germain first reported a position in ALNY in Q2 2025 and has held it in 5 quarters since. The position peaked at $3.72M in Q3 2025. 785 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

D.J. St. Germain held 7,834 shares of Alnylam Pharmaceuticals worth $2.36M as of Q2 2026.
D.J. St. Germain sold 18 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $5.43K.
Alnylam Pharmaceuticals made up 0.08% of D.J. St. Germain's portfolio in Q2 2026, its #130 holding.
D.J. St. Germain first reported a position in Alnylam Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
D.J. St. Germain's Alnylam Pharmaceuticals position peaked at $3.72M in Q3 2025.
785 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on D.J. St. Germain's 13F filing for Q2 2026, filed 21 Jul 2026.